Logo

Takeda's Exkivity (mobocertinib) Receives the US FDA's Approval as the First Oral Therapy for EGFR Exon20 Insertion+ NSCLC

Share this

Takeda's Exkivity (mobocertinib) Receives the US FDA's Approval as the First Oral Therapy for EGFR Exon20 Insertion+ NSCLC

Shots:

  • The approval is based on the P-I/II trial evaluating Exkivity (160 mg) in 114 patients with EGFR Exon20 insertion+ NSCLC who received prior Pt-based therapy
  • The results demonstrated ORR (28%) as assessed by IRC & 35% as per investigator- m-DoR (17.5mos.)- m-OS (24mos.)- and m-PFS (7.3mos.) as per IRC
  • Exkivity is a TKI inhibitor designed to selectively target EGFR Exon20 insertion mutation & has received PR- BTD- FTD & ODD from the FDA. Additionally- the US FDA has approved Thermo Fisher’s Oncomine Dx Target test as an NGS CDx for Exkivity to identify NSCLC patients with EGFR Exon20 insertions

Ref: Business Wire | Image:Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions